We’re proud to call Alameda our home and share with the San Francisco Business Times the history of our space (all the way back to WWI and WWII) and ability to invest in world-class talent to help us engineer the future of medicine. Read about our #biotech community: bizjournals.com/sanfrancisco/n…

What does it take to rewrite the story of disease? Our CEO Benjamin L. Oakes shared with Big Think how a mission-driven team like Scribe can redefine what is possible in medicine with #CRISPR. His insights on leadership, innovation, and bold vision 👇 bigthink.com/business/leade…

🧬 Cell & Gene Meeting on the Mesa by Alliance for Regenerative Medicine (ARM) #CGMesa25 📅 October 6 at 1:45 PM MST 🗣️ Corporate presentation by CEO Benjamin L. Oakes Read our full press release: businesswire.com/news/home/2025…

Starship goes interdimensional during Flight 10. One of the most insane vapor cones I've ever seen.

At #ESCCongress for the latest on #CRISPR gene editing treatments for cardiometabolic disease? On Monday, CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇

Check out our press release for more #ESCCongress presentation details: businesswire.com/news/home/2025… European Society of Cardiology #ESCCongress #WCCardio

Remarkable that US spending on pharmaceuticals is just ~1.6% of GDP. Amazingly good value for money considering the welfare gains. (And especially given the extent to which the US subsidizes the rest of the world.)

If you’ll be in New York for the Cantor Global Healthcare Conference, our CEO Benjamin L. Oakes and CFO David Parrot will be on site and available for one-on-one meetings between Sept. 3-5. Interested in connecting? Reach out through our website 👉 scribetx.com/contact

Building on the legacy of many, I'm incredibly excited that we have successfully translated our polygenic risk scores into a validated clinical assay Mass General Brigham Broad Institute, orderable by any clinician in the US today. 🧬To order: massgeneralbrigham.org/en/research-an… 🧬Announcement:

Taher Modarressi, MD Mass General Brigham Broad Institute Mass General Brigham Research Mass General Heart @BroadGenomics Harvard Medical School MassGeneral Medicine MGH Cardiovascular Research Center CGM at MGH AHA Council on Genomic and Precision Medicine AHA Science The easiest is to select ‘Saliva.’ The kit will be shipped with a prepaid mailer, inclusive of the $255 cost. And yes the price is the same, regardless of whether all 8 conditions or a subset is chosen. We are working on improving the order process but we aren’t a company & just

At Scribe, we run on teamwork and purpose – in and out of the lab. #JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉

We've spent billions on treatments that patients can't stick to. 𝗔𝗻𝗱 𝘀𝘁𝗶𝗹𝗹, 𝗲𝘃𝗲𝗿𝘆 𝟯𝟰 𝘀𝗲𝗰𝗼𝗻𝗱𝘀, 𝘀𝗼𝗺𝗲𝗼𝗻𝗲 𝗱𝗶𝗲𝘀 𝗳𝗿𝗼𝗺 𝗰𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲. That's more than cancer, accidents, and diabetes combined. We’ve been solving the

Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇

Meet Scribe at #CGMesa25 in Phoenix 🌵 Our CFO David Parrot will be onsite at the Alliance for Regenerative Medicine (ARM) Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease. Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.

We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9! 🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates

United States needs China the same way Batman needs Joker. Without China, the West is culturally set for complacency and decline. United States had no business in space until Soviets Sputnik-scared them. And I can only hope that Shanghai biotechs killing it on all fronts will

Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease. "I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵

Scribe's ELXR platform underpins STX-1150, our #CRISPR-based therapy designed to lower LDL-C and address cardiovascular disease effectively. Thanks to Mar de Miguel for interviewing our CEO Benjamin L. Oakes and showcasing our innovative ELXR engineering work! ESGCT Clarivate

How can we transform the standard of care for heart disease? ❤️‍🩹 Join us at #TCT2025 this Saturday to hear from our CEO Benjamin L. Oakes, who will share promising #CRISPR gene editing and epigenetic silencing strategies at Cardiovascular Research Foundation's TCT Conference MedTech Innovation Forum.